Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRBC1/2 CAR-NK Cell Therapy in Relapsed/Refractory T-Cell Lymphoma
NCT07164560Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2026
- Primary completion
- Jan 2029
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TRBC1/2 CAR-NK cells in peripheral T-cell lymphoma (PTCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
TRBC1/2 CAR-NK cells
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07164560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164560.